Citations 2
P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB
Nakamura, R., Hendricks, R., Dokhaei, Romina, Susilo, Monica Damayani, Wilson, D., Trudel, S., Cohen, Aaron B. , Harrison, S. J. , Krishnan, A., Adamkewicz, J. I., Li, M., Wong, C., Cooper, J., Sumiyoshi, T., Krishnan, A., Fonseca, Rodrigo
HemaSphere | June 30, 2022 | Volume: 6 | Issue: No issue available | Pages: 852-853
P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?
Popat, Rakesh , Badros, Ashraf , Kumar, Seema, Cohen, Alan R., Manier, Salomon , Voorhees, Peter M. , Rifkin, Robert M. , Martin, T., Jeng, Bennie H. , Lee, H, Berdeja, J. G., Jadhav, Vinay, Tosolini, A, Eliason, L, Palumbo, A, Trudel, S., Richardson, PG, Popat, Rakesh , Rodríguez‐Otero, Paula , Gay, Francesca , Chari, Ajai , Weisel, Katja C , Farooq, Asim V. , Chng, Wee Joo , Palumbo, Antonio , Dimopoulos, Meletios Α. , Lonial, Sagar , Terpos, Evangelos
HemaSphere | April 6, 2022 | Volume: 6 | Issue: No issue available | Pages: 18-18